📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly uses specific growth figures (U.S. spine 7.4% day-adjusted, 19 consecutive weeks, 58% sequential enabling tech growth) and directly addresses prior challenges (supply chain resolved, Nevro near breakeven). Language is forward-looking and optimistic with precise metrics.

Q3 2025

Confident Specific

Management expressed strong confidence using superlatives like 'extremely pleased', 'record results', 'stellar results', and 'exceptional'. They provided specific growth percentages, margin figures, and upward guidance revisions, e.g., 'Non-GAAP diluted earnings per share of $1.18, growing 42.6%' and 'free cash flow was a record for the third quarter'.

Q4 2025

Confident Specific

Management used strong positive language such as 'record Q4 performance', 'momentum continued and accelerated', 'beating our target by $30 million and nearly an entire year ahead of plan', and provided specific figures like $2.939B revenue, $3.98 EPS, 25.7% revenue growth in Q4, and 10% U.S. spine growth.

Q1 2026 latest

Confident Specific

Management used strong language like 'exceptional results', 'impressive beginning', 'thrilled with our results', and provided specific numbers (e.g., 27% revenue growth, 64.7% EPS growth) and raised EPS guidance, indicating confidence with concrete performance details.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. The core spine business continues to gain share with consistent 10% growth, margins are expanding faster than expected, and management raised full-year EPS guidance. The shift to more lease/rental models for robots shows strategic flexibility to drive recurring implant revenue, which should support long-term profitable growth. However, the Nevro business remains a drag with anticipated further near-term weakness, and the Enabling Technologies revenue mix change may cap top-line acceleration. Key metrics to watch next quarter: Nevro revenue trajectory, gross margin progression toward 70%+, and whether new SCRIPT products gain traction.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Globus Medical Q1 2026 revenue $759.9M, up 27%, non-GAAP EPS $1.12, raising full-year EPS guidance.

Revenue & Profitability

First quarter 2026 revenue was $759.9 million, growing 27% as reported and 25.5% on a constant currency basis. GAAP net income was $124.3 million ($0.90 per diluted share), while non-GAAP net income was $154.9 million ($1.12 per diluted share), a 64.7% increase over the prior year. Adjusted EBITDA margin was 32.3%.

Outlook

Management reiterated full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP EPS guidance to $4.70-$4.80, citing strong momentum and margin expansion. The hospital capital expenditure environment for robotics is described as healthy, though the mix of deals is shifting toward leases and rentals. No material geopolitical risks were identified.

Growth Drivers

Key growth levers include U.S. Spine (10% growth for the third consecutive quarter), international spine (double-digit growth), trauma (30.4% growth), and Enabling Technologies (21% growth). Competitive recruiting, cross-selling, and robotic pull-through are core strategies. New product launches such as the SCRIPT patient-specific spacers and rods are expected to drive further share gains.

Balance Sheet & CapEx

Capital expenditures in Q1 2026 were $39.6 million, or 5.2% of sales. The capital allocation strategy prioritizes internal R&D, building implant sets for the sales force, share repurchases ($390 million remaining under the current authorization), and evaluating complementary M&A.

Margins

Adjusted gross profit margin was 69.2% in Q1 2026, up from 67.3% in the prior year, driven by fixed cost leverage, favorable sales mix, and manufacturing synergies. Management expects FY2026 adjusted gross margin to be in the 69%–70% range, with a long-term target of mid-70s. Adjusted EBITDA margin for the base business was 34.8%.

Key Risks

Management flagged the expected lumpiness in Nevro revenue as the business is restructured, with a potential further decline before recovery. No material impact from geopolitical risks or the Kaiser strike was noted. Competitive dynamics may pressure pricing and deal timelines.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-06

Q2 2026 delivered 6% revenue growth (9% excluding Nevro), record non-GAAP EPS, and 35.4% adjusted EBITDA margin. U.S. and international spine, trauma, and neuromonitoring drove strong results, while Enabling Technologies and Nevro remained soft. Full-year guidance was reaffirmed, with EPS guidance raised on margin expansion.

Q1 2026 Q1 2026 2026-05-07

Q1 2026 delivered 27% revenue growth and 64.7% non-GAAP EPS growth, driven by strong U.S. and international spine, trauma, and enabling technologies. Margin expansion and operational efficiency led to raised EPS guidance, while Nevro is expected to recover in H2 2026.

Q4 2025 Q4 2025 2026-02-24

Delivered record 2025 results with 16.7% revenue growth and 30.8% non-GAAP EPS growth, driven by strong U.S. spine, enabling tech, and trauma segments. 2026 guidance raised for EPS, with continued margin expansion, robust product launches, and successful integration of NuVasive and Nevro.

Q3 2025 Q3 2025 2025-11-06

Q3 2025 saw record revenue, EPS, and free cash flow, led by strong U.S. spine and trauma growth, with Nevro integration ahead of schedule and accretive to earnings. Guidance for 2025 was raised for both revenue and EPS, reflecting confidence in continued profitable growth.

Q2 2025 Q2 2025 2025-08-07

Q2 2025 saw 18.4% revenue growth and 14.1% non-GAAP EPS growth, driven by strong U.S. spine and trauma performance, successful Nevro integration, and robust product innovation. Guidance for 2025 is reaffirmed, with continued focus on operational excellence and market share gains.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.